Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)

NCT00133250 Phase 4 COMPLETED

The purpose of this study is to assess whether abciximab is associated with additional benefit in patients with AMI treated with PCI after high dose clopidogrel loading.

Details

Lead sponsor	Deutsches Herzzentrum Muenchen
Phase	Phase 4
Status	COMPLETED
Enrolment	800
Start date	2003-06
Completion	2008-03

Conditions

• Myocardial Infarction

Interventions

• Abciximab
• Placebo Heparin Sodium

Primary outcomes

• Left ventricular infarct size calculated as the final perfusion defect at follow-up scintigraphic study — 5-7 days

Countries

Austria, Germany